<DOC>
	<DOCNO>NCT00647049</DOCNO>
	<brief_summary>The purpose study determine whether combined chemotherapy [ rituximab plus high dosage methotrexate ( max . 2 cycle ) follow arabinoside/thiotepa ( max . 2 cycle ) follow high dosage carmustin/thiotepa ] follow peripheral blood stem cell transplantation effective treatment cerebral Non Hodgkin lymphoma [ PCNSL ] .</brief_summary>
	<brief_title>Freiburg ZNS-NHL Study</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<criteria>group A : first diagnosis PCNSL , histologically confirm group B : relapse progression PCNSL MTX contain chemotherapy age 18 65 year legally incompetent , physically mentally incapable give consent write sign date informed consent legal representative possible patient manifestation lymphoma outside CNS seropositive HIV severe pulmonary , cardiac , hepatic , renal impairment neutrophil count &lt; 2.000/µl , platelet count &lt; 100.000/µl pulmonary disease IVC &lt; 55 % , DLCO &lt; 40 % cardiac ejection fraction &lt; 50 % , uncontrolled malign arrhythmia creatinine &gt; 1,5 mg % creatinineclearance &lt; 50ml/min bilirubin &gt; 2mg/dl ascites pleural effusion ( &gt; 500ml ) pregnancy r lactation woman childbearing potential without sufficient contraception participation another clinical trial within last 30 day prior begin parallel study know current drug alcohol abuse know hypersensitivity methotrexate , cytarabine , thiotepa , BCNU rituximab , leukovorin , dexamethasone , neupogen neulasta .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>